Anna Lucsok on competitive strategy
From Zynex COO highlights strong reimbursement strategy and growth in non-opioid pain management · · Proactive Investors
“This is one of the main reasons why we've been successful in this industry. And this is what makes us stand out among our competitors.”
On , Anna Lucsok, Chief Operating Officer at ZYNEX INC, spoke about competitive strategy during Zynex COO highlights strong reimbursement strategy and growth in non-opioid pain management on Proactive Investors.
About Anna Lucsok
Anna Lucsok, Chief Operating Officer at Zynex, has described the company's focus on non-opioid pain management products, including electrotherapy devices like the NexWave, as well as complementary items such as bracing and hot/cold therapy. In interviews from December 2024 and March 2025, Lucsok stated that Zynex accepts all insurances and has a reimbursement department that navigates coverage with third-party payers. She noted that the company's sales force has grown to 350 representatives, with a goal of reaching 800, and that per-rep performance has doubled compared to two years prior. Lucsok also mentioned that Zynex recently reached one million patients and plans to remain focused on the U.S. market for the next three to five years before expanding internationally. Lucsok said that a patient survey of 20,000 respondents indicated a 60% reduction in pain and a 50% reduction in medication use after using the NexWave device. She described Zynex's mission as becoming a "one stop shop" for patients seeking alternatives to opioids and pain medication, and stated that the company works with thousands of doctors across the U.S. who prescribe its devices. Lucsok has been COO since January 2021, with responsibilities including sales, reimbursement, operations, quality, IT, HR, compliance, and legal.